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Abstract
Tumor hypoxia is associated with low rates of cell proliferation and poor drug delivery, limiting
the efficacy of many conventional therapies such as chemotherapy. Since many macrophages
accumulate in hypoxic regions of tumors, one way to target tumor cells in these regions could be
to use genetically engineered macrophages that express therapeutic genes when exposed to
hypoxia. We describe here our use of a new mathematical model to simulate and compare the
effects of conventional cyclophosphamide therapy with those induced when macrophages are used
to deliver hypoxia-inducible cytochrome P450 to locally activate cyclophosphamide. Our
mathematical model describes the spatio-temporal dynamics of vascular tumor growth and treats
cells as distinct entities, each with its own cell cycle and subcellular signalling machinery.
Moreover, the model simulates the delivery of systemically-applied therapies by a dynamic
vascular network. We used this model to determine both the impact on tumors of combining
conventional chemotherapy with macrophage-based gene delivery, and how the efficacy of
macrophage-based therapies may be enhanced by pre-loading the cells with magnetic
nanoparticles and applying a magnetic field to the tumor site.
Major Findings—Our results predict that combining conventional and macrophage-based
therapies would be synergistic, producing greater anti-tumor effects than the additive effects of
each form of therapy. Moreover, we found that timing is crucial in this combined approach with
efficacy being greatest when the macrophage-based therapy is administered shortly before or
concurrent with chemotherapy. Lastly, we show not only that macrophage delivery of therapeutic
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genes is markedly enhanced using the magnetic approach described above, but also that the
disorganised nature of tumor blood vessels means that this enhancement depends mainly on the
strength of the applied field, rather than its direction. This may be important in the treatment of
non-superficial tumors where generating a specific orientation of a magnetic field may prove
difficult. In conclusion, we demonstrate that mathematical modelling can be used to design, and
maximize the efficacy of, combined therapeutic approaches in cancer.
Keywords
macrophage; gene therapy; hypoxia; mathematical model; combination therapy
Introduction
Hypoxic areas of tumors are notoriously hard to target with conventional drugs (due to their
poor vascularisation), yet treatment success often hinges upon the elimination of such areas
since any remaining hypoxic tumor cells often secrete cytokines that cause the tumor to
revascularise and regrow (1, 2). A possible anti-cancer strategy, outlined in Figure 1,
exploits the innate ability of macrophages, a type of immune cell, to accumulate within
hypoxic tumor regions (3, 4). Tumor spheroid experiments in vitro have shown that when
macrophages are genetically modified to express a prodrug-activating enzyme (cytochrome
P450) during hypoxia, tumor cell kill can be achieved (following conversion of the prodrug
cyclophosphamide into its cytotoxic moiety by enzyme-expressing hypoxic macrophages)
(3). For the same kind of treatment to be successful in vivo, assuming intravenous injection
of the prodrug and macrophages, a substantial number of macrophages would need to
extravasate from the bloodstream and localise at the tumor mass. To increase delivery to the
tumor site, we have devised a magnetic approach in which monocytes (macrophage
precursor cells, found in the bloodstream) are pre-loaded with magnetic nanoparticles by
phagocytosis (5). In vivo experiments in mice have demonstrated the potential of this
technique; systemic injection of such magnetic macrophages, in combination with
application of an externally-applied magnetic field near the tumor, increased three-fold the
number of macrophages accumulated within the tumor (5). However, such experiments have
not yet been attempted using “therapeutically-armed” macrophages (i.e. macrophages that
express a therapeutic gene). While these in vitro and in vivo experimental results are highly
promising, a number of questions remain. For example, for the prodrug-enzyme pair used in
the in vitro experiments (3), it is not clear which cells are targeted. Previous mathematical
modelling of tumor spheroids suggests that whilst such engineered macrophages target
active drug production to hypoxic regions, the dependence of tumor cell death on mitosis
means that cell-kill is predominantly outside the hypoxic layer (6). It remains of interest to
determine how the in vitro model predictions will translate to vascular tumors in vivo. It is
also important to determine the in vivo efficacy of macrophage-based gene-therapy, to
compare it to conventional therapies, to understand the possible synergistic benefits of
combination therapy, and to assess the improvements in therapeutic outcomes that may be
possible using the magnetic approach (5).
There is a long history of using mathematical models to study the growth of solid tumors
and their response to therapy (7, 8, 9, 10). Compartmental models have been formulated as
systems of ordinary differential equations (e.g. (11, 12)). Alternatively, partial differential
equation (PDE) models have been proposed to explain the spatial structure within avascular
tumor spheroids (6, 13) and the variations in vessel density within vascular tumors (14).
Approaches that consider individual cells include models for angiogenesis and drug delivery
(15), and hybrid models that also include PDE descriptions of tumor growth (16). A
common feature of these models is that individual cells are represented as point objects,
whereas alternative approaches represent cells as deformable spheres (17), or as a set of sites
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on a lattice (18). In separate work, Alarcón and co-workers (19, 20, 21, 22) proposed a
multiscale model for vascular tumor growth which combines blood flow, angiogenesis,
vascular remodelling, and multiple interacting cell populations. This framework is unique in
its extensive coupling across scales, exemplified by the way that vascular remodelling
influences, and is influenced by, the growth dynamics of the cell populations, which are
themselves regulated by models for subcellular signaling pathways including an oxygen-
regulated cell cycle model (22).
Existing multiscale models of tumor growth differ in their emphasis on subcellular
processes, cell-cell interactions, cell movement, nutrient delivery, and biomechanics. Most
such models do not yet address issues of cancer therapy. There are several compartmental
models for cancer therapy, addressing, for example, the emergence of a rapidly proliferating
subpopulation under the selection pressure imposed by therapy (23); modelling
immunotherapy (24); endothelial cell-targeted anti-Bcl-2 therapy (25), and modelling
treatment via an oncolytic virus (26). Spatially-structured, PDE models for therapy include a
study of anti-angiogenic gene therapy (27), and predictions of drug responses in breast
cancer (28).
In this paper we extend the multiscale model of solid tumor growth (22) to account for
conventional chemotherapy with cyclophosphamide, macrophage-based gene-therapy, and
enhanced delivery of therapeutically-armed magnetic macrophages. Model simulations
suggest that, compared to conventional chemotherapy, macrophage treatment may
preferentially target tumor cells, and leave a smaller remaining fraction of hypoxic tumor
cells. We also observe that, for tumors growing in tissues with relatively isotropic vascular
networks (i.e. with no dominant vessel orientation), enhanced macrophage extravasation
depends predominantly on the strength of the applied field, rather than its direction. Finally,
we show how combination therapies may act in a strongly synergistic manner, particularly
when macrophage-therapy is applied shortly before, or concurrent with, conventional
therapy.
Quick Guide to Equations and Assumptions
We represent the tissue as a regular two-dimensional lattice (spacing Δx) with an
embedded vascular network. Each site can contain a number of cells and has associated
concentrations of oxygen, VEGF, prodrug and drug (Figure 1).
Major assumptions – Cells
Each normal and cancer cell has Ordinary Differential Equation models for the cell cycle
and p53-VEGF signalling. On completion of the cell cycle, if space is available, daughter
cells are placed at the same or a neighbouring site — otherwise the parent cell cycle
restarts, and no daughter cell is produced. Cancer cells enter and leave quiescence
according to the local oxygen concentration, and die if quiescent for too long. Normal
cell apoptosis occurs if p53 exceeds a threshold which is lower when the cell is
surrounded by cancer cells (so that the tumor microenvironment is hostile to normal
cells).
All cell types move by a random walk, biased by the space available and gradients in
VEGF. The probability of a cell moving from site x to y in time Δt is
Equation 1
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N(x,t) is the number of cells and V(x,t) the VEGF concentration at site x. D is the
maximum random motility, Nm the carrying capacity for movement, χ the chemotactic
sensitivity (χ=0 for normal and cancer cells), and dx,y the distance from x to y.
Major assumptions – Vasculature
We prescribe the pressure at a set of inlets and outlets, and compute the flow and
pressure drop for each vessel segment (using the Poiseuille approximation) by imposing
conservation of mass at each node. Vessel radii adapt to the wall shear stress,
intravascular pressure, and flow (22, 29). We prescribe a haematocrit of 45% in vessels
that sustain flow and zero otherwise. Segments with low flow are pruned if their wall
shear stress remains below  for a period longer than Tprune.
Angiogenesis
On each time-step Δt, the probability of an endothelial tip cell sprouting from a vessel at
site x is
Equation 2
where Vsprout is the VEGF concentration at which the probability is half-maximal (22).
Prsprout(x,t)=0 if the number of cells at x exceeds the carrying capacity for sprouting,
, or if a sprout has already emerged within an exclusion radius, Rex (since Delta-
Notch signalling inhibits adjacent cells from sprouting). Tip cells perform random walks,
biased by VEGF, according to Eq. 1. When a tip cell moves, a stationary endothelial cell
is left behind—thus sprout contiguity is maintained by endothelial cell proliferation (30).
Anastomosis occurs when a tip cell moves to a site already occupied by a sprout or
vessel, establishing flow in the new vessel. If anastomosis does not occur within Tprune of
tip cell emergence, then the sprout dies.
Major assumptions – Diffusibles
Equations for oxygen, VEGF, drug and prodrug take the form:
Equation 3
where U(x,t) is the tissue concentration of interest, Ublood(x,t) the concentration in the
blood, Su(x,t) the cell- and environment-dependent production/removal rate, and δu the
linear decay rate. ρv(x,t) is the vascular density and ψu the vascular permeability to U.
Major assumptions – Therapy
Conventional
Active drug is present in the blood plasma due to conversion of cyclophosphamide in the
liver. After boluses at times , plasma levels decay exponentially, so that the tissue drug
concentration, Q(x,t), is governed by Eq. 3, with Sq≡0 and
 for . Here, H(x,t) is the haematocrit
in the vessel at x.
Drug action
If Q(x,t)>Qcrit any cell at site x intercalates active drug. Normal and cancer cells with
drug intercalated die upon attempting cell-division.
Macrophages & magnetic field
On one time-step the probability of macrophage extravasation from a vessel at x is
Owen et al. Page 4
Cancer Res. Author manuscript; available in PMC 2012 December 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Equation 4
where R(x,t) is the radius of the vessel (if present) through x at time t, L(x,t) is the length
of the vessel segment,  is the macrophage level in the
vessel following a single injection of macrophages (Hin is the reference inflow
haematocrit), the extravasation rate increases with VEGF (31), and Av is the VEGF
concentration at which it is half-maximal. In Eq. 4, αm represents the baseline
extravasation rate and βm determines the increase due to magnetic effects, vmag is the
macrophage velocity due to the magnetic field, and the effect of the magnetic field is
mediated by |vmag · n(x,t)|, the component of vmag that points into the vessel wall (32).
Extravasation can only occur if the number of cells at x is less than . Tissue
macrophages do not proliferate, have a normally distributed survival time (mean = 90
days, s.d. = 9 days), and move chemotactically according to Eq. 1 (33). This has no
magnetic component since the magnetic force on macrophages in the tissue is negligible
(see Supplementary Material).
The prodrug and active drug concentrations, P(x,t) and Q(x,t), are governed by Eq. 3,
with  and Qblood(x,t)=0. Active drug is produced
from prodrug via hypoxic macrophages expressing cytochrome P450:
Equation 5
Prodrug conversion means that Sp(x,t) = −Sq(x,t).
Materials and Methods
The main components of the multiscale model are described in detail in (22). New features
introduced in this paper include tissue macrophages (and the effect of magnetic
nanoparticles on their extravasation), additional diffusible species (drug and prodrug), the
effect that the active drug moiety has on proliferating cells, and the local conversion of
prodrug to drug by hypoxic macrophages. Figure 1 illustrates the model framework, and the
Quick Guide to Equations and Assumptions provides an overview of the key model
components. Further model details and parameter values can be found in the supplementary
material and in (22).
The model is formulated on a regular two-dimensional lattice with an embedded vascular
network. Each lattice site can contain a number of cells of different types and has associated
concentrations of oxygen, Vascular Endothelial Growth Factor (VEGF), prodrug and drug.
Different submodels describe behaviour at the subcellular, cellular and macroscopic
(diffusible and vascular) scales. The spatial scales of interest range from 10μm (cells, vessel
diameters) to mm (tissue size), while the timescales vary from minutes (signalling, protein
synthesis), to hours (cell proliferation and movement) and days/weeks (tumor doubling time,
angiogenesis). Coupling between the different submodels is achieved in several ways. For
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example, local oxygen levels, which are determined at the macroscale, influence both cell
cycle progression and VEGF production at the subcellular level. Conversely, VEGF
production modulates angiogenesis at the macroscale and this, in turn, controls oxygen
delivery to the tissue. In particular, lack of oxygen stimulates VEGF expression, which
promotes macrophage extravasation and angiogenesis. In the vascular layer, the vessel radii
are updated using a structural adaptation law similar to that proposed by Pries et al. (22, 29).
We stress that the submodels we use illustrate how such a multiscale model can be
assembled: the framework we present is general, with considerable scope for incorporating
alternative submodels.
A particular form of conventional chemotherapy is modelled by assuming that the prodrug
cyclophosphamide (CPA) is delivered systemically and is converted by the enzyme
cytochrome P450, principally in the liver, to its active, cytotoxic moiety. Hence, for
conventional chemotherapy we model the pharmocokinetics of the active moiety blood
concentration by exponential decay following weekly boluses of CPA. For macrophage-
based gene therapy, we model macrophage extravasation and chemotactic migration to
hypoxic regions, in order to deliver hypoxia-inducible-cytochrome P450 to hypoxic areas of
tumors, hence localising CPA conversion to those regions. To model the enhanced delivery
of macrophages loaded with magnetic nanoparticles, we modify the extravasation rate
accordingly (see Eq. 4 and the supplementary material). As magnetic nanoparticle-loaded
macrophages approach the high-field region, the z-axis component of the field gradient
dominates so that the particles are generally pulled towards the magnetic field source. Once
macrophages have extravasated, we do not include any magnetic component to their
movement, since the magnetic force on macrophages in the tissue is negligible (see
supplementary material).
For each control and therapeutic scenario considered we performed multiple virtual tissue
simulations (stochastic realisations). Since cell movements, angiogenic sprouting and
macrophage extravasation are probabilistic processes, on each time step different
simulations (generated by different initialisations of a random number generator) can yield
subtly different outcomes, which can lead to significant changes in long-term behaviour.
Thus it is essential to consider both the mean behaviour and the degree of variation between
simulations.
We used our model to generate ten simulations of a normal tissue, in a 2mm × 2mm domain,
with a reproducible characteristic vascular density (vascular surface area per unit volume,
mean±standard error = 9.9±0.19 mm2/mm3). Implanting a small tumor into such a
computational tissue leads to the spread of the tumor, which develops regions of hypoxia
and stimulates angiogenesis, such that after 100 days the tissue has a higher vascular density
(18.6±0.23 mm2/mm3), and a quiescent fraction of 8.2±0.74% (percent of cancer cells that
are quiescent). These values are consistent with published data (see Section D.1 of the
supplementary material for further details of model validation). We then applied therapy to
these simulated tumors, using conventional chemotherapy, macrophage-based gene therapy
(with and without enhancement using magnetic nanoparticles), and various combinations.
Results
Conventional chemotherapy
Figure 2A shows snapshots from a typical simulation in which conventional chemotherapy
is applied in weekly boluses beginning three weeks after tumor implantation. After each
bolus, the active drug concentration is maximal close to blood vessels, but otherwise
relatively homogeneously distributed throughout the tissue. A significant number of cells are
killed following each treatment, in locations where cell proliferation coincides with a high
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drug concentration. Cancer cells are preferentially targeted because their rates of
proliferation are higher than those for normal cells, but the tumor recovers after each
treatment. Figure 2B shows the average rate of cell division, drug concentration and rate of
cell kill from day 21 (the start of therapy) to day 100, and reinforces the perception that the
drug distribution and cell-kill are widespread and indiscriminate.
Figure 4A shows how the total numbers of normal and cancer cells change over time, in the
simulated tissue, for control (no therapy) and conventional therapy. For the ten therapeutic
simulations, the tumor cell number declines dramatically following each drug bolus, and
then recovers before the next treatment. The drug dose is insufficient to eliminate all tumor
cells, and hence the tumor eventually colonises the entire domain after the final round of
therapy. For these examples (of control and unsuccessful conventional therapy) the number
of normal cells drops to zero, and the total tumor cell number is limited. These outcomes are
artefacts of the limited size of the in silico tissue domain: in vivo the tumor would be
embedded in a larger tissue and surrounded by more normal cells.
Figure 5A illustrates dose-response data (at 100 days after tumor implantation, i.e. 2 days
after the 12th treatment) as the maximal concentration of active drug in the blood (Qbolus)
varies. As the dose increases, the tumor burden decreases, with a half maximal effective
concentration (EC50) of Qbolus≈12. For smaller doses, the quiescent fraction increases
relative to control. For sufficiently large doses the tumor is eliminated, although too large a
dose prevents normal tissue recovery.
Macrophage therapy
Figure 3A shows snapshots from a typical simulation of macrophage therapy (see
Supplementary Movie 1). Three weeks after tumor implantation a single bolus of
macrophages is applied, together with the first of 20 weekly doses of prodrug. The
individual snapshots and cumulative data (Figure 3B) show that the macrophage therapy
targets hypoxic cells but does not kill them when they are hypoxic (macrophages and drug
are co-located, but cell-kill occurs in a band outside this area). In spite of this, cell-kill is
predominantly in a region that is complementary to that for conventional therapy, and
macrophage therapy preferentially targets tumor cells rather than normal cells.
Figure 4B shows the temporal dynamics of cell numbers in the simulated tissue. We show
the mean in the control case, and the mean and ten simulations for macrophage therapy.
Each therapeutic simulation follows a similar temporal pattern. In some cases the tumor is
almost eliminated at t ≈ 23 days. At intermediate times (60-90 days) the impact of
successive treatments diminishes, since the tumor does not develop the degree of hypoxia
seen for the first round of treatment, and hence prodrug activation is less extensive. At about
90 days the macrophages begin to die, and the therapeutic effect declines until after day 130
it is negligible.
For this prodrug dose (Pbolus=250) the reduction in overall tumor burden (compared to
untreated control) is similar to that for conventional therapy with Qbolus=12 (compare the
tumor cell numbers in Figure 4A and B), and both cases correspond approximately to half-
maximal efficacy (see Figure 5). However, the quiescent fraction at 100 days is lower with
this example of macrophage therapy (6±0.48%) than with the equivalent conventional
therapy (11.3±1.7%), indicating that the macrophage therapy preferentially targets hypoxic
tumor cells. In addition, at early times (21-50 days) the normal cell population declines more
slowly with macrophage therapy than in either the control or conventionally treated cases.
Figure 5B illustrates dose-response data for macrophage therapy, showing half-maximal
efficacy at Pbolus≈250. For Pbolus>50, the quiescent fraction decreases with prodrug dose.
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For sufficiently large doses the tumor is eliminated, although too large a dose is harmful to
normal tissue.
Effect of magnetic nanoparticles on macrophage extravasation
Experiments in vivo have shown a threefold enhancement in the infiltration of macrophages
loaded with magnetic nanoparticles (macrophage proportion of tumor mass: 4.9% without,
and 16.9% with, a magnetic field) (5). We determined parameter values so that simulated
infiltration into ten established tumors, with differing emergent vascular networks, gave the
same degree of magnetic enhancement. Figure 6A shows that, at 5 hours, the mean
proportion of macrophages (over ten simulations) is 4.9±0.6% in the absence of the
magnetic field. This increases to 15.8±1.3% (17.9±1.5%) with the field in the horizontal
(vertical) direction. Over one week we see a pattern of rapid infiltration followed by a
gradual settling to a steady density in the tissue, as the level of macrophages in the
bloodstream falls to zero. This infiltration has a weak effect on the size of the tumor (Figure
6A). Figure 6B shows the cumulative locations of macrophage extravasation after 5 hours,
illustrating that the magnetic field increases the extravasation rate at specific vessels
according to their orientation relative to the magnetic field. Nevertheless, Figure 6C shows
that the overall pattern of macrophage localisation within the tissue is similar for both
orientations of the field.
Combination therapies
Figure 4C summarises results from simulations combining the conventional and macrophage
therapies illustrated in Figures 2 and 3. Three weeks after tumor implantation a single bolus
of macrophages is applied, together with the first of 20 weekly doses of prodrug and active
drug. In all ten simulations, the combined treatment eliminates the tumor, and in 8/10 cases
the normal tissue recovers. This might be expected, since the individual conventional and
macrophage therapies gave 54% and 45% reductions in tumor size respectively. Therefore,
we consider whether there are synergistic benefits of combination therapies where the
individual therapies have smaller efficacies.
Figure 7A summarises the results for the control case and seven therapeutic combinations
(conventional alone, Qbolus=11; macrophages alone, Pbolus=120; and combinations with and
without magnetic enhancement). The conventional and macrophage therapies have a limited
effect on the tumor size (average reductions of 27% and 21% respectively), but combining
them gives an average reduction of 94%. However, the outcome is highly variable (for time
courses see Figure S5 of the supplementary material). In 6/10 cases the tumor is eliminated
(supplementary Movie 2 shows an example of tumor elimination); in the remaining four
cases the tumor is reduced in size during treatment, but regrows after the last round of
therapy. Combining macrophages with magnetic nanoparticles and a magnetic field gives a
significant improvement over macrophages alone, due to the increased macrophage
infiltration and consequently higher levels of prodrug activation within the tumor. The
results with Qbolus=11, Pbolus=120 (tumor elimination in 6/10 cases) can be improved further
by combining conventional drug delivery with macrophages and enhancing macrophage
extravasation using magnetic nanoparticles; the tumor is eliminated in 10/10 simulations, for
both directions of the magnetic field (Figure 7A).
Finally, delivering macrophage after conventional therapy gives worse outcomes over a
range of lags from 1 hour up to 4 days (Figure 7B). Macrophage therapy 1 hour before
conventional therapy is beneficial, with tumor elimination in 7/10 cases (rather than 6/10
with simultaneous delivery). However, greater timing differences again give worse
outcomes. Additional examples of combination therapy and altered timing can be found in
Figure S6 of the Supplementary Material.
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Discussion
We have extended a multiscale mathematical model of vascular tumor growth to simulate
the response to conventional chemotherapy and a new, macrophage-based gene therapy that
targets hypoxic tumor regions. We also use the model to investigate the potential for
enhancing the delivery of such macrophage-based therapies by pre-loading macrophages
with magnetic nanoparticles and applying a magnetic field near the tumor. The overarching
aim of this work is to build upon data from in vitro and in vivo experiments (3, 5) in order to
generate experimentally testable predictions and hypotheses about a novel therapeutic
strategy.
Our model simulations indicate that the macrophage-based therapy, with hypoxia-inducible
cytochrome P450 activating cyclophosphamide, targets hypoxic cells but does not kill them
when they are hypoxic. The macrophage-based therapy is more effective against tumor cells
than normal ones, because of the greater degree of hypoxia found in tumor compared to
normal tissue. While both conventional and macrophage-based approaches may yield similar
reductions in tumor volume, the hypoxic volume fraction of the macrophage-treated tumor is
typically smaller than that of its conventionally-treated counterpart, making the tumor more
responsive to follow-on treatment with drugs that target rapidly proliferating cells.
Consequently, it is unsurprising that combination therapy is synergistic, yielding reductions
in tumor volume in excess of those expected if the treatments act independently. When
macrophage treatment is successful, it is self-limiting in nature, since elimination of the
tumor also eliminates the hypoxia that drives the therapeutic effect. Magnetically loading the
macrophages enhances their effect, and, for the relatively isotropic vascular networks
studied here, the increase in delivery does not depend strongly on the direction of the
magnetic field. Since tumor blood vessels are often highly disorganized (34), this result may
be important for non-superficial tumors, for which it may be difficult to generate a magnetic
field with a specific orientation. In many cases, we find considerable variability in outcomes
— the same treatment applied to different simulated tissues may either successfully
eliminate the tumor or allow it to persist. Hence it is essential to consider, as in this paper,
multiple virtual tissue simulations in order to capture average behaviour and the degree of
variation that can be expected. Finally, we find that, for combination therapies, timing can
be crucial — it is best to apply macrophage therapy slightly in advance of conventional
therapy.
We have investigated the sensitivity of the anti-tumor response to variations in key
therapeutic parameters. Our simulations reveal that the response to conventional and
macrophage-based therapies is nonlinear: close to the EC50, small changes in drug/prodrug
dose produce large changes in the anti-tumor response, but away from the EC50 the dose-
response relationship is relatively flat (Figure 5). Our major findings about the predicted
synergy and timing dependence of combination therapy persist for different drug and
prodrug doses (compare Figure 7 and Figure S6 of the supplementary text). Our results are
also robust to changes in cell cycle times, and in the order in which the components of the
computational algorithm are executed (see Section D and Figures S7 and S8 of the
supplementary text).
A major advantage of simulations such as those used here is that it is possible to interrogate
closely the state of the system as it develops over time, in order to identify key features that
regulate the therapeutic response. Here we have used this approach to go beyond
macroscopic measures (such as tumor size and hypoxic fraction) and to characterise where
within the tissue the therapy is active, and how this relates to, for example, regions of
hypoxia, macrophage localisation and cell proliferation. In future work it would be
interesting to track the positions of cells when they intercalate drug (i.e. when they became
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committed to drug-induced cell death), to assess the extent to which cells move out of
hypoxic regions and then die, and to compare this with the extent to which they intercalate
drug outside of the hypoxic region. We anticipate that this balance will depend on the degree
of tumor cell motility.
Our results suggest many directions for future experimental research in this area. For
example, the simulations reveal that the enzyme-prodrug combination considered here
produces high levels of active drug in hypoxic regions, but kills cells in surrounding, non-
hypoxic zones (similar results were obtained from a PDE model for macrophage gene
therapy (6)). This feature arises because cell-kill requires attempted cell-division, which
occurs preferentially at higher oxygen concentrations. It should be feasible experimentally to
test our predictions about the locations of drug production and therapeutic tumor cell lysis
by, for example, immunohistochemical staining of tissue sections to locate active drug, sites
of DNA replication, and apoptotic cells. Supplementary staining for hypoxia and endothelial
cells would provide additional spatial information against which to test our model
predictions.
A number of model extensions are possible to investigate alternative therapies and to
improve the applicability of our model. For example, we could investigate the efficacy of
macrophages engineered to deliver anti-angiogenic or other vascular-targeting agents.
Alternatively, we could simulate the effect of combining cytotoxic macrophage-based
therapy (e.g. using cyclophosphamide) with vascular-disrupting agents such as
Combretastatin A-4 (35), which we would expect to increase tumor hypoxia (and hence
enhance prodrug activation). Our model could also be used to investigate whether
application of an alternating field to the tissue containing the magnetically-loaded
macrophages can generate a sufficiently large (and localised) heating effect to stimulate cell
death in that region (36). On the other hand, it may be important to consider the potential
pro-tumor effects of macrophages (such as the secretion of angiogenic factors) (37), and
how a patient's blood monocytes and resident tissue macrophages might compete with the
introduced genetically modified macrophages. Other related therapies that our model could
be adapted to study include gene transfer of cytochrome p450 into tumor cells (38), and the
use of macrophages to target a therapeutic virus to hypoxic tumor regions, under the control
of a tumor tissue specific promoter (39). The latter avoids potential problems of prodrug
activation at non-tumor sites of hypoxia, such as may be found in patients with
atherosclerotic plaques or rheumatoid arthritis (40). In the future we will extend our model
to 3 space dimensions. Based on results comparing untreated tumor growth in 2D and 3D1,
we anticipate that the qualitative behaviour will be unchanged for the various individual and
combined therapies studied here.
In conclusion, we have demonstrated how our state-of-the-art mathematical model of
vascular tumor growth can be used to test the efficacy of a new anti-cancer treatment and to
support a programme of experimental work to optimise its efficacy. Our model provides
insight into the in vivo mechanism of action of macrophage-based therapy, and can be used
to generate experimentally-testable predictions (for example, that using macrophage therapy
in combination with standard chemotherapy will provide synergistic benefits, and that such
therapies should be administered near-simultaneously to achieve the best response). Our
modelling can help to identify the most productive avenues for using macrophages as a
novel system to deliver gene therapy, and can be extended to consider a variety of
alternative therapeutic strategies.
1H Perfahl, H M Byrne, T Chen, V Estrella, T Alarcón, A Lapin, R A Gatenby, R J Gillies, MC Lloyd, P K Maini, M Reuss, M R
Owen: Multiscale modelling of vascular tumor growth in 3D: the roles of domain size and boundary conditions, submitted.
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Figure 1.
Outline of macrophage-based cancer therapy and mathematical model framework. Key
interactions are shown, in particular that tissue oxygen depends on the vascular layer, that
VEGF drives angiogenesis and macrophage migration, that drug kills tumor cells, and that
hypoxic macrophages activate prodrug under hypoxia. In addition, extravasation of
macrophages loaded with magnetic nanoparticles is enhanced most strongly in vessels that
are perpendicular to the direction of action of a magnetic field.
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Figure 2.
Typical simulation showing how a tumor responds to conventional chemotherapy with
cyclophosphamide, via weekly boluses (Qbolus=12) that start three weeks after tumor
implantation. (A) The state of the simulated tissue before and two days after treatments at
t=21, 28, 42 and 84 days, and the average rate of cell division, drug concentration and rate of
cell-kill over each 2-day period. (B) The rate of cell division, average drug concentration
and rate of cell-kill over days 21 to 100.
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Figure 3.
Typical simulation of macrophage therapy via a single bolus of engineered macrophages
three weeks after tumor implantation, coincident with the first of 20 weekly boluses of the
prodrug cyclophosphamide (Pbolus=250). (A) The state of the simulated tissue before and
two days after treatments at t=21, 28, 35 and 84 days, and the average rate of cell division,
drug concentration and rate of cell-kill over each 2-day period. (B) The average macrophage
density, rate of cell division, drug concentration, and rate of cell-kill over days 12 to 100.
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Figure 4.
The response to therapy over time. (A) Conventional therapy, Qbolus=12. Each bolus leads
initially to tumor regression and then regrowth. (B) Engineered macrophages accumulate
after injection on day 21. Weekly prodrug boluses (Pbolus=250) cause the tumor to shrink
initially and then to regrow. (C) Engineered macrophages and conventional therapy
(Pbolus=250, Qbolus=12). In 10/10 simulations the tumor is eliminated and normal tissue
recovers in 8/10 cases. (Colour version: Fig. S4 in supplement)
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Figure 5.
Dose-response data at 100 days for tumor growth with conventional and macrophage
therapy. (A) Response to conventional therapy across a range of drug doses (Qbolus). Half-
maximal efficacy is reached at Qbolus≈12. (B) Response to macrophage therapy across a
range of prodrug doses (Pbolus). Half-maximal efficacy is reached at Pbolus≈250. (A,B) In
both cases, drug/prodrug doses above the EC50 can promote recovery of normal tissue, but if
the dose is too large normal tissue is also damaged further. Bars represent mean values
(n=10) and individual simulations are indicated by points. The point style indicates whether
or not the tumor and/or normal cells persist at the end of each simulation (at 200 days).
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Figure 6.
(A) Series of curves showing dependence on the magnetic field of macrophage infiltration
into a tumor, where the macrophages have been loaded with magnetic nanoparticles. Each
curve is the mean of ten simulations. The macrophage fractions after five hours, without and
with a magnetic field, are in agreement with experimental data in (5). (B) Cumulative
macrophage extravasation at five hours, without a magnetic field, and with a magnetic field
oriented in the x- and y-directions. The magnetic field increases the extravasation rate at
specific vessels according to their orientation relative to the magnetic field. (C) The
distribution of quiescent cancer cells, infiltrated macrophages, and the vascular network at
five hours. The overall pattern of macrophage localisation is similar for both orientations of
the field.
Owen et al. Page 19
Cancer Res. Author manuscript; available in PMC 2012 December 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 7.
Summary data, showing the state at 100 days, for combination therapies starting three weeks
after tumor implantation. (A) Comparison of conventional therapy (Qbolus=11), macrophage
therapy (Pbolus=120), magnetically enhanced macrophage therapy, and simultaneously
delivered combinations. For combined conventional and macrophage therapy, the average
reduction in tumor size is greater than would be expected from the sum of the individual
effects. The results also illustrate the variability in response that can occur. (B) One
combination (Qbolus=120, Qbolus=11), which gives tumor elimination in 6/10 cases, with
various timing shifts of macrophage therapy relative to conventional therapy. “-1h” indicates
macrophage therapy is 1 hour before conventional therapy, etc. Macrophage therapy 1h and
6h prior to conventional therapy gives a small advantage (tumor elimination in 7/10 cases).
All other tested timing shifts give worse responses. (A,B) Bars represent mean values (n=10)
and individual simulations are indicated by points. The point style indicates whether or not
the tumor and/or normal cells persist at the end of each simulation (at 200 days).
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